EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC-ND 4.0

Oral Azacitidine Maintenance After CPX ‐351 in Transplant‐Ineligible Patients With Therapy‐Related or Myelodysplasia‐Related Acute Myeloid Leukemia

Caroline Fileni iD, Edmond Chiche iD, David Swoboda iD, Alexander Coltoff, Rami Komrokji iD, Geoffrey Uy iD, Sarah Bertoli, Lenaig Le Clech, Mael Heiblig iD, Ludovic Gabellier iD, Patrick Lawrence iD, Lydia Kretschmer und 7 weitere

American Journal of Hematology · 09.10.2026

DOI: 10.1002/ajh.70521 ↗

Kurz gefasst

Leserbrief in der Zeitschrift American Journal of Hematology, online erschienen am 09.10.2026. Verfasst von Caroline Fileni und 18 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Nice University Hospital, Nice, France. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To the Editor, CPX-351 has become a standard intensive induction regimen for older patients with therapy-related acute myeloid leukemia (t-AML) and acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) [1,2].Although allogeneic hematopoietic cell transplantation (allo-HCT) remains the preferred consolidation strategy for eligible patients in first remission, a substantial proportion of older or unfit patients are not candidates for transplantation [3].To note, median overall survival (OS) for patients not transplanted after CPX-351 in the pivotal study was only 14 months [4].For these patients, the optimal post-remission strategy remains an unmet clinical need.Oral azacitidine (oral AZA; CC-486) prolongs OS in transplant-ineligible patients with AML in first remission, based on the QUAZAR AML-001 trial [5].However, patients with secondary AML were underrepresented in that study, and all patients had received conventional 7 + 3 chemotherapy.Thus, whether oral AZA provides benefit following CPX-351 remains uncertain.We conducted an international, real-world, retrospective, multicenter study evaluating oral AZA maintenance in adults with t-AML or myelodysplasia-related acute myeloid leukemia (AML-MR) who achieved first remission after CPX-351 and were not eligible for allo-HCT.Patients were identified across 13 centers in France, United States, Italy, Germany, and Australia between January 2020 and July 2024.Eligible patients had newly diagnosed t-AML or AML-MR; had not previously received a hypomethylating agent; achieved a first complete remission (CR1, CRh1, or CRi1) following CPX-351; were not eligible for allo-HCT and subsequently received oral AZA maintenance.Oral AZA was administered at the approved dose of 300 mg once daily for 14 days of a 28-day cycle.For comparison, we assembled a hybrid control cohort of 112 non-transplanted patients with t-AML or AML-MR who achieved CR(i)1 after CPX-351 but did not receive maintenance therapy or allo-HCT.A synthetically derived dataset from the

Autor:innen und Institutionen

  • Hematology Department, Nice University Hospital, Nice, France.
  • Tampa General Hospital Cancer Institute, Tampa, Florida, USA.
  • Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
  • Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Centre Hospitalo-universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Toulouse, France.

ORCID-Profile: Caroline Fileni, Edmond Chiche, David Swoboda, Rami Komrokji, Geoffrey Uy, Mael Heiblig, Ludovic Gabellier, Patrick Lawrence, Christoph Röllig, Fabio Guolo, David Sallman, Thomas Cluzeau

Zitieren

APA

Fileni, C., Chiche, E., Swoboda, D., Coltoff, A., Komrokji, R., Uy, G., Bertoli, S., Le Clech, L., Heiblig, M., Gabellier, L., Lawrence, P., Kretschmer, L., Röllig, C., Wei, A. H., Guolo, F., Lemoli, R. M., Lancet, J., Sallman, D., & Cluzeau, T. (2026). Oral Azacitidine Maintenance After CPX ‐351 in Transplant‐Ineligible Patients With Therapy‐Related or Myelodysplasia‐Related Acute Myeloid Leukemia. American Journal of Hematology. https://doi.org/10.1002/ajh.70521

Vancouver

Fileni C, Chiche E, Swoboda D, Coltoff A, Komrokji R, Uy G, et al. Oral Azacitidine Maintenance After CPX ‐351 in Transplant‐Ineligible Patients With Therapy‐Related or Myelodysplasia‐Related Acute Myeloid Leukemia. American Journal of Hematology. 2026. doi:10.1002/ajh.70521

BibTeX
@article{Fileni2026,
  author = {Fileni, Caroline and Chiche, Edmond and Swoboda, David and Coltoff, Alexander and Komrokji, Rami and Uy, Geoffrey and Bertoli, Sarah and Le Clech, Lenaig and Heiblig, Mael and Gabellier, Ludovic and Lawrence, Patrick and Kretschmer, Lydia and Röllig, Christoph and Wei, A H and Guolo, Fabio and Lemoli, Roberto Massimo and Lancet, Jeffrey and Sallman, David and Cluzeau, Thomas},
  title = {Oral Azacitidine Maintenance After CPX ‐351 in Transplant‐Ineligible Patients With Therapy‐Related or Myelodysplasia‐Related Acute Myeloid Leukemia},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70521}
}
Kostenlos starten →